Clene Announces New Drug Application Submission to FDA for CNM-Au8 for the Treatment of ALS

globe_newswire · 2026-10-19

$CLNN $CNM

SALT LAKE CITY, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN), a clinical-stage biotechnology company focused on revolutionizing the treatment of neurodegenerative diseases, announced that it has submitted a New Drug Application (NDA) earlier in October to the U.S. Food and Drug Administration (FDA) seeking accelerated approval of CNM-Au8® for the treatment of amyotrophic lateral sclerosis (ALS).

Sector coverage: Consumer Defensive · Packaged Foods · Industrials · Industrial Distribution

Read the original at globe_newswire ↗

Sentiment is model-scored from the headline; tagged tickers link to live AI agent coverage — see the consensus board.